Adamax: The Complete Guide

Adamax is an investigational heptapeptide identified in vendor and community literature as Ac-Met-Glu-His-Phe-Pro-Gly-Pro-AG-NH2 (Ac-MEHFPGP-AG-NH2) — an N-acetylated Semax core with an adamantyl-AG C-terminal cap copied from the P21 peptidomimetic.

Lineage (two parent molecules):

• Semax (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP) — a synthetic ACTH(4–7) analog with a Pro-Gly-Pro C-cap, developed at the Russian Academy of Sciences Institute of Molecular Genetics in the 1980s. Russian-registered nasal solution since the late 1990s for cognitive disorders, asthenia, and acute ischemic stroke. Important: the ACTH(4–10) fragment is the “behavioral / nootropic” portion of ACTH, not the adrenocortical-stimulating fragment. Semax was specifically designed to keep the cognitive effect while losing HPA-axis activation.
• P21 / P021 (Ac-Asp-Gly-Gly-Leu-Ala-Gly-NH2 with adamantyl modification) — a hexapeptide derived from CNTF residues 148–151, developed by the Iqbal lab at the NYS Institute for Basic Research in Developmental Disabilities (Staten Island). The adamantyl group is added to improve proteolytic stability and blood-brain-barrier penetration. Foundational paper: PMID 20600002 (Li et al., FEBS Lett 2010).

Adamax = N-acetyl Semax + adamantyl-AG cap from P21.

The composition is uniformly described in vendor and community literature but is not described in any PubMed-indexed paper. The exact stereochemistry of the adamantyl substitution is not consistently reported across vendor sources; the molecule has never been independently characterized in indexed primary research.

The "Ada-" prefix is adamantyl, not adrenal.

Some vendor and community pages frame Adamax as a Khavinson-family adrenal-axis bioregulator. That framing is wrong. “Ada-” refers to the adamantyl chemical-modification group at the C-terminus, copied from P21. There is no Khavinson-group paper on Adamax in any database. The KEDW tetrapeptide that some sources attach to Adamax actually belongs to a different compound — Pancragen, which targets the endocrine pancreas, not the adrenal cortex.

Regulatory status:

• FDA (US): not approved. No NDA, no IND on file. Sold as a research-use-only chemical.
• EMA (EU): not approved.
• Russia: not registered as a pharmaceutical or supplement. The parent Semax IS registered (nasal solution 0.1% and 1%); Adamax is not.
• New Zealand Medsafe: identified in border seizures of designer drugs with a recommendation to schedule it as a prescription medicine — one of the few formal regulatory citations of Adamax anywhere.
• WADA 2026: not listed by name. As an ACTH(4–10) analog, S2.4 (Corticotrophins, where ACTH analogs are explicitly named) is plausibly applicable; as an unapproved investigational substance, S0 is also plausible. Athletes should not assume Adamax is permitted without consulting their governing body.

Direct evidence on Adamax: none. Every mechanism claim below is extrapolated from the parent peptides; the Adamax molecule itself has not been studied in PubMed-indexed primary research.

From Semax (parent #1, MEHFPGP):

• Indirect BDNF / NGF upregulation in rat hippocampus (Dolotov et al., PMID 16996037).
• Mesolimbic dopamine modulation — only in the presence of stimuli like amphetamine, not at baseline (PMID 16362768).
• Anti-inflammatory / immune gene-expression modulation in rat focal-ischemia model (Dmitrieva et al.).
• No HPA-axis / cortisol activity. The ACTH(4–10) family was explicitly designed to retain behavioral effects via central melanocortin receptors while losing adrenocortical activation. Vendor framing of Adamax as having “HPA-axis interactions” or “regulating stress hormones via adrenal effects” is not supported by the parent literature.

From P21 / P021 (parent #2, Ac-DGGLAG-NH2 + adamantyl C-cap):

• BDNF / TrkB / PI3K / Akt / GSK3β-Ser9 phosphorylation — the canonical proposed pathway (PMIDs 24702821, 27400746).
• Dentate-gyrus neurogenesis and synaptic plasticity in C57Bl/6 mice (PMID 20600002, foundational paper).
• Reduction of tau hyperphosphorylation in 3xTg-AD mouse models (PMIDs 25046994, 26401692, 28387677, 28655344, 36291618).
• CDKL5 deficiency model — recent in vitro and in vivo CDKL5-/- mouse data (PMID 39592934, J Neurodev Disord 2024).
• The adamantyl modification design intent is improved BBB penetration and proteolytic stability vs. the unmodified hexapeptide.
• No published human clinical trial. Phanes Biotech holds development rights for Alzheimer’s; preclinical-only as of 2026-05.

What gets extrapolated to Adamax (vendor framing):

Vendor pages typically claim dual MC3R/MC4R activation with preferential MC4R binding, increased BDNF expression, enhanced TrkB receptor sensitivity, and improved BBB penetration via the adamantyl moiety. None of these has been measured for the Adamax molecule itself.

Honest summary: if you want to know what Adamax does, the most accurate answer is “we’re assuming it does what Semax + P21 do, separately, in animals.” That’s not the same as “Adamax does X” — it’s an inference, not a measurement.

Banner: there is no Adamax-specific primary literature. Every “benefit” below is parent-extrapolation. Evidence-tier is labeled per row.

Proposed Benefit	Source	Evidence Tier
Cognitive enhancement / focus	Semax Russian clinical lit (PMIDs 33418449, 16212268); vendor anecdote	Indirect — parent only
BDNF upregulation	P21 mouse data (PMID 20600002)	Indirect — parent only
Neuroprotection	P21 mouse models (PMIDs 25046994, 36291618)	Indirect — parent only
Memory / learning improvement	P21 + Semax animal data	Indirect — parent only
Stroke recovery	Semax Russian lit (PMID 33418449); Russian registered indication	Indirect — parent only; Russian-only
HPA / cortisol / stress-hormone modulation	None	No evidence for any direction; vendor framing not supported
Tau-pathology reduction (Alzheimer’s)	P21 / P021 in 3xTg-AD mice (Iqbal-lab series)	Indirect — parent only; preclinical

The CDKL5 finding (PMID 39592934, J Neurodev Disord 2024) is on P021, not on Adamax. Some vendor pages cite it as Adamax evidence — that is a misattribution.

No human clinical trial of Adamax has been published. The dose ranges below reflect vendor and community convention only. They are not validated clinical protocols and are not anchored to any published PK study.

Route	Common Range	Frequency
Intranasal spray	200–600 µg/spray, 1–3 sprays/day; total ~600–1800 µg/day	Daily, morning preferred
Subcutaneous injection	300–1000 µg/day, often titrated 100 → 500 → 1000 µg	Daily, morning preferred
Oral / sublingual capsule	Less common; dose poorly defined in vendor lit	Daily

Cycle convention (community):

• Continuous use 4–12 weeks then break, OR
• 5 days on / 2 days off with longer continuous runs.

Dosing notes:

• Avoid late-day dosing. Insomnia is the most consistent community-reported side effect.
• Intranasal is the most common route — mirrors the Semax registered formulation.
• None of these dose figures is anchored to any published trial of Adamax.

Standard SC peptide reconstitution applies. For a typical 10 mg lyophilized vial:

• Add 2 mL bacteriostatic water → final concentration 5 mg/mL (5000 µg/mL).
• On a U-100 insulin syringe, 1 unit = 50 µg.
• So a 500 µg dose = 10 units; a 1000 µg dose = 20 units.

Storage:

• Lyophilized: stable at room temperature short-term; refrigerate for longer storage.
• Reconstituted: refrigerate. Use within 28 days (standard BAC water beyond-use date).
• Nasal solution form: store refrigerated; protect from light.

For the full reconstitution protocol, see the Bacteriostatic Water guide.

No published safety data on Adamax exists. No FAERS / EudraVigilance / Yellow Card entries. Community reports parallel the standard Semax profile:

• Insomnia — especially with afternoon or evening dosing. Most consistent community report.
• Mild stimulation — described as “more stimulating than Semax” by some users.
• Nasal irritation with the intranasal route.
• Mild injection-site reactions with SC route (redness, transient soreness).
• Mild headache, especially during the first week of use.

The adamantyl modification has no documented additional toxicity from peptide-class human data. (The adamantyl-amine antivirals like amantadine and rimantadine are different chemistry — small-molecule adamantyl amines, not peptides — and their side-effect profile does not transfer to Adamax.)

• Pregnancy / breastfeeding — no safety data; avoid.
• History of seizure disorder — theoretical concern from BDNF / TrkB pathway activation extrapolated from P21 mechanism. Not measured for Adamax.
• Active malignancy with TrkB-expressing tumor types (some neuroblastomas, glioblastomas, certain lung/breast adenocarcinomas) — theoretical; no measured signal but the BDNF / TrkB pathway is implicated in these lineages.
• Concurrent stimulant use (amphetamines, modafinil, high-dose caffeine) — insomnia / sympathomimetic stack risk.
• Active hypertension — no data either way; ACTH-fragment lineage warrants caution.
• Athletes subject to anti-doping testing — do not use without consulting your governing body. WADA S2.4 (corticotrophins, ACTH analogs explicitly named) and S0 (non-approved substances) are both plausibly applicable.

This section exists because vendor and community sources frequently misidentify Adamax. If you’ve seen any of these claims, they’re wrong:

Wrong: “Adamax is the Khavinson tetrapeptide Lys-Glu-Asp-Trp (KEDW).”

KEDW is a real peptide, but it’s Pancragen, not Adamax. Pancragen targets the endocrine pancreas (β-cell support, glucose tolerance). Anchoring evidence: PMIDs 21246099, 25946840 (Goncharova rhesus monkey trial: “Pancragen (tetrapeptide Lys-Glu-Asp-Trp) on endocrine function of the pancreas…”). See the Pancragen guide for the full identity.

Wrong: “Adamax is a Khavinson adrenal-axis bioregulator.”

The Khavinson short-peptide family follows an organ-targeting naming convention (Cartalax → cartilage, Prostamax → prostate, Pancragen → pancreas, Cardiogen → heart, Bronchogen → bronchi). The closest legitimate “adrenal Khavinson product” is Glandokort (A-17), an oral capsule containing a bovine-adrenal polypeptide extract sold in Russia as a supplement. Glandokort is not a synthetic short peptide and not Adamax. Zero PubMed-indexed papers exist on Glandokort.

Wrong: “The 'Ada-' in Adamax means adrenal.”

It means adamantyl — the chemical-modification group at the C-terminus, copied from the P21 peptidomimetic. The naming is structural, not organ-targeting.

Adjacent compounds that are NOT Adamax:

• Semax — parent #1; Russian-registered nasal solution; substantial published lit.
• P21 / P021 — parent #2; Iqbal-lab Alzheimer’s preclinical candidate; no human trial.
• N-Acetyl Semax / N-Acetyl Semax Amidate — related Semax modifications popular in the nootropic community; share the N-acetyl modification but lack the adamantyl-AG cap. Different molecules.
• Selank — sister Russian-Academy peptide; GABAergic anxiolytic; not a parent of Adamax.
• Cerebrolysin — porcine brain extract, multi-component; different family entirely.